Payment overview · 2025
General Payments
$2,235.72
88 reported records · 26 companies
Healthcare provider profile · identity verified
Hollie Temples Newbern
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRUNSWICK, GA · NPI 1063939619
Verified facts
What the public records show
CMS Open Payments records show Hollie Temples Newbern received $2,235.72 in general payments during 2025 across 88 reported records.
Medtronic, Inc. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$792.36 | 35.4% | 10 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $173.75 | 7.8% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.32 | 6.4% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $121.35 | 5.4% | 5 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $86.63 | 3.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.53 | 3.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.02 | 3.7% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $77.66 | 3.5% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $66.46 | 3.0% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $62.24 | 2.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.83 | 2.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.67 | 2.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $54.17 | 2.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.33 | 2.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.72 | 2.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.31 | 1.8% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $33.09 | 1.5% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $31.35 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.64 | 1.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $25.62 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.92 | 1.1% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $24.73 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.86 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.78 | 0.9% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $17.98 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.40 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,737.96 | 84 |
| Travel and Lodging | $497.76 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $725.75 | 9 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $173.75 | 17 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $121.35 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.96 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.96 | 9 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $86.63 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.53 | 4 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $77.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $77.34 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $66.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.35 | 3 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $62.24 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $57.83 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $54.17 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.36 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.72 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 307 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 244 | 77 |
| Gabapentin | Gabapentin | 178 | 55 |
| Trazodone Hcl | Trazodone Hcl | 167 | 48 |
| Lisinopril | Lisinopril | 147 | 48 |
| Omeprazole | Omeprazole | 143 | 45 |
| Metformin Hcl | Metformin Hcl | 125 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 36 |
| Alprazolam | Alprazolam | 116 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 40 |
| Sertraline Hcl | Sertraline Hcl | 103 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 30 |
| Tramadol Hcl | Tramadol Hcl | 98 | 25 |
| Simvastatin | Simvastatin | 94 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 32 |
| Montelukast Sodium | Montelukast Sodium | 85 | 23 |
| Potassium Chloride | Potassium Chloride | 85 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 23 |
| Lorazepam | Lorazepam | 70 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 29 |
| Bupropion Xl | Bupropion Hcl | 67 | 23 |
| Furosemide | Furosemide | 64 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 13 |
| Alendronate Sodium | Alendronate Sodium | 63 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 21 |
| Meloxicam | Meloxicam | 63 | 22 |
| Famotidine | Famotidine | 61 | 21 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Eliquis | Apixaban | 57 | 14 |
| Ozempic | Semaglutide | 54 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 14 |
| Prednisone | Prednisone | 50 | 28 |
| Valacyclovir | Valacyclovir Hcl | 49 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 12 |
| Ezetimibe | Ezetimibe | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 15 |
| Allopurinol | Allopurinol | 43 | 14 |
| Azelastine Hcl | Azelastine Hcl | 42 | 16 |
| Glipizide Er | Glipizide | 42 | 14 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Carvedilol | Carvedilol | 40 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 13 |
| Estradiol | Estradiol | 39 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 16 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Glipizide | Glipizide | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Atenolol | Atenolol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,235.72 · 88 records | Medtronic, Inc. | AREXVY, Auvelity, CAPLYTA, Dexcom G6 Transmitter, General - Pain Management, JARDIANCE, Kerendia, Korlym, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, QULIPTA, QUTENZA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, Senza, TRELEGY ELLIPTA, TWIIST, The Cologuard Plus Collection Kit, UBRELVY, Venclose Maven Catheter, Wegovy, Yorvipath, ZAVZPRET, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error